Biogen Inc. BIIB shares are trading higher after the company was granted accelerated FDA approval for its ADUHELM Alzheimer's candidate.
The accelerated approval has been granted based on data from clinical trials demonstrating the effect of ADUHELM on reducing amyloid beta plaques, a biomarker that is reasonably likely to predict clinical benefit, in this case a reduction in clinical decline, said in the company's press release.
The company reported 'In clinical trials, ADUHELM reduced amyloid beta plaques by 59%-71% at 18 months of treatment.'
Biogen discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases.
Biogen's stock was trading about 43% higher at $408.24 at the time of publication. The stock has a 52-week high of $468.55 and a 52-week low of $223.25.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.